Compugen (NASDAQ:CGEN) and Vaxart (NASDAQ:VXRT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, earnings, valuation and dividends.
Earnings & Valuation
This table compares Compugen and Vaxart’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Vaxart||$8.90 million||2.59||-$3.40 million||N/A||N/A|
Vaxart has higher revenue and earnings than Compugen.
Risk & Volatility
Compugen has a beta of 1.11, meaning that its share price is 11% more volatile than the S&P 500. Comparatively, Vaxart has a beta of 0.06, meaning that its share price is 94% less volatile than the S&P 500.
This is a summary of recent ratings and recommmendations for Compugen and Vaxart, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Compugen presently has a consensus price target of $9.00, indicating a potential upside of 147.25%. Given Compugen’s stronger consensus rating and higher possible upside, analysts plainly believe Compugen is more favorable than Vaxart.
This table compares Compugen and Vaxart’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider and Institutional Ownership
20.8% of Compugen shares are owned by institutional investors. Comparatively, 7.6% of Vaxart shares are owned by institutional investors. 9.5% of Compugen shares are owned by company insiders. Comparatively, 44.8% of Vaxart shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Compugen beats Vaxart on 8 of the 12 factors compared between the two stocks.
Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel and Europe. The company's therapeutic pipeline consists of immuno-oncology programs against novel drug targets in the areas of unmet medical needs in various cancer types and patient populations. Its product pipeline consists of COM701, a monoclonal antibody designed to block the interaction of PVRIG with its cognate ligand, PVRL2; CGEN-15001T, an immuno-oncology therapeutic program for ILDR2; and COM902, a therapeutic antibody candidate for its TIGIT program. The company's pipeline also comprises therapeutic proteins include CGEN-15001, a fusion protein drug candidate for autoimmune diseases, including extracellular domain of ILDR2 and an IgG Fc domain. Compugen Ltd. has a clinical trial collaboration with Bristol-Myers Squibb Company to evaluate the safety of COM701 in combination with Bristol-Myers Squibb's programmed death-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors. The company was incorporated in 1993 and is headquartered in Holon, Israel.
Vaxart, Inc., a clinical-stage company, focuses on developing oral recombinant vaccines based on its proprietary oral vaccine delivery platform. The company's platform delivers various recombinant protein antigens, such as those used in influenza, hepatitis B, and human papilloma virus (HPV) vaccines, as well as other recombinant vaccines. Its development programs include oral tablet vaccines that are designed to protect against norovirus, seasonal influenza, and respiratory syncytial virus, as well as a therapeutic vaccine for HPV. The company is headquartered in South San Francisco, California.
Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.